COPD Co-infection With Tuberculosis on Th17 Cell Differentiation

NCT ID: NCT04966052

Last Updated: 2021-07-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2018-04-01
• Study Completion Date: 2020-06-01

Brief Summary

This project will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and measure the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of factors such as TNF-α, IFN-γ and IL-17 in pulmonary blood and alveolar lavage fluid.

Detailed Description

Chronic obstructive pulmonary disease (COPD) and tuberculosis are major global health problems, and acquired and acquired immunity play an important role in COPD and tuberculosis, and there is an interaction between COPD and tuberculosis, but the exact mechanism is not clear. Pre-existing TB infection is an independent risk factor for COPD and can aggravate pulmonary function and increase hospitalization and mortality in COPD patients. In COPD patients, Th1 and Th17 cells are involved in the development of COPD and emphysema through activation of macrophages and recruitment of neutrophils, while matrix metalloproteinases (MMPs) of macrophage and neutrophil origin are involved in the formation of tuberculosis cavities, and cytokines such as TNF-α, IFN-γ, IL-17 are involved in the mechanism of their destruction, IL-17 restricts the expression of HIF-1α to inhibit the development of TB granulomas, and CT analysis revealed that combined TB exacerbates emphysema in COPD patients. The above evidence suggests that tuberculosis plays an important role in the formation of emphysema in COPD. In this project, we will observe and follow up the changes of pulmonary function and CT in patients with smoking combined with pulmonary tuberculosis, and examine the ratio of Th1 cells, Th17 cells, macrophages and neutrophils and the secretion of TNF-α, IFN-γ, and IL-17 in pulmonary blood and alveolar lavage fluid.

Conditions

Tuberculosis Infection; Chronic Obstructive Pulmonary Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

COPD combined with TB group

COPD combined with pulmonary TB infection

No intervention

Intervention Type: OTHER

No intervention

COPD non-TB control group

COPD combined without pulmonary TB infection

No interventions assigned to this group

TB non-COPD control group

pulmonary TB infection without COPD

No interventions assigned to this group

Non-smoking non-TB control group

Non-smoking without pulmonary TB infection

No interventions assigned to this group

Interventions

No intervention

No intervention

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Clinical diagnosis of COPD
• age ≧ 40

Exclusion Criteria

• Presence of other chronic respiratory diseases other than COPD, such as asthma, bronchiectasis, interstitial lung disease, etc.
• History of chest and lung surgery.
• History of malignancy.
• Autoimmune disease.
• Long-term oral glucocorticoids, immunosuppressants and inhaled glucocorticoids.
• Mental abnormalities, cognitive impairment, inability to cooperate with pulmonary function and other tests.
• Acute stage of infection, such as lung infection, urinary tract infection and gastrointestinal tract infection, etc.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Beijing Geriatric Hospital

OTHER

Sponsor Role: collaborator

Peking University Third Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yongchang Sun, MD

Role: PRINCIPAL_INVESTIGATOR

Peking University 3rd Hospital

Locations

Peking University Third Hospital

Beijing, Beijing Municipality, China

Countries

China

References

Gai X, Cao W, Rao Y, Zeng L, Xu W, Wu H, Li G, Sun Y. Risk factors and biomarkers for post-tuberculosis lung damage in a Chinese cohort of male smokers and non-smokers: protocol for a prospective observational study. BMJ Open. 2023 Oct 9;13(10):e065990. doi: 10.1136/bmjopen-2022-065990.

Reference Type: DERIVED

PMID: 37813532 (View on PubMed)

Other Identifiers

M2017390

Identifier Type: -

Identifier Source: org_study_id